First National Bank of Omaha Acquires Shares of 27,553 Thermo Fisher Scientific Inc. $TMO

First National Bank of Omaha bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, Holdings Channel.com reports. The firm bought 27,553 shares of the medical research company’s stock, valued at approximately $13,895,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Brighton Jones LLC boosted its holdings in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC raised its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. Darwin Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $170,000. Raymond James Financial Inc. boosted its stake in Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after purchasing an additional 53,542 shares during the period. Finally, California State Teachers Retirement System grew its holdings in Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after buying an additional 2,262 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity

In other news, CEO Marc N. Casper sold 4,608 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $586.12, for a total value of $2,700,840.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 52,053 shares of company stock valued at $30,643,589. 0.33% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TMO. Stifel Nicolaus set a $650.00 price target on shares of Thermo Fisher Scientific in a report on Wednesday, August 5th. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Jefferies Financial Group restated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Finally, Wolfe Research began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Stock Up 4.3%

TMO stock opened at $614.32 on Thursday. The company’s 50 day moving average is $536.26 and its 200 day moving average is $508.51. The stock has a market cap of $227.14 billion, a price-to-earnings ratio of 33.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period in the previous year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.